Veritas In Silico
Kawasaki, JP · Founded 2016 · 15 employees on LinkedIn · 5 known investors
Find your way into Veritas In Silico
109 people in our graph share verified history with the Veritas In Silico team — schools, employers, funds. One of them is your warm intro.
Ann Miura-Kounlockedknows Shingo Nakamura · together at Yale University (overlapped)
×4knows the team · via Yale University
knows the team · via Catalent
knows the team · via Kenichi Ohmae Graduate School of Business
knows the team · via Dow Chemical
×3knows the team · via Innovation Network Corporation Of Japan
Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.
Founders & leadership
SN
Shingo NakamurainCEOShingo Nakamura holds a doctorate in synthetic organic chemistry from Nagoya University and has conducted postdoctoral research in molecular biology at Yale University. He spent seven years as a principal investigator at Takeda Pharmaceutical Company, followed by roles in sales and business development at Dow Chemical Company and Catalent Pharma Solutions, with additional academic affiliations at Japanese universities.
Investors · 5
In the news
Frequently asked questions
- What does Veritas In Silico do?
- Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.
- Who are Veritas In Silico's investors?
- Veritas In Silico's investors include Global Brain, KDDI Open Innovation Fund, Nippon Venture Capital, Shinsei Capital Partners, SMBC Venture Capital.
- Where is Veritas In Silico headquartered?
- Veritas In Silico is headquartered in Kawasaki, JP.